These two laggards are Wall Street's top picks in the rapidly emerging cannabis industry.
These three healthcare stocks could be outstanding additions to your portfolio.
Which of these healthcare stocks is the better buy right now?
Pfizer moves to acquire the cancer specialist in a deal valued at $11.4 billion.
These three diabetes stocks have a lot going on this month.
With the industry possibly cooling off, here are the names to remember.
Which of these elite biotechs is the better buy right now?
Aphria is the cheapest pot producer in all of Canada by a wide margin.
Amicus Therapeutics and Array BioPharma are two top growth stocks to consider buying now.
The biopharma stock is continuing to experience volatility today.
Wall Street may be vastly underestimating Cronos' long-term value proposition.
These three biotech stocks should turn out to be outstanding long-term growth vehicles.
Which of these top dividend-paying pharma stocks is the better buy right now?
Which of these fallen stars has the more compelling comeback story?
AbbVie and Pfizer are both undergoing a radical makeover. Which company should investors trust to come out even stronger?
These stocks are bargains.
Geron hints at a way forward for imetelstat in myelofibrosis, but the market isn't buying it.
MacroGenics shares jumped in response to another major clinical update today.
Catalyst Pharmaceuticals and Novavax have had tough go of it in May. Could better days be close at hand?
Is Tilray's strong first-quarter report a good reason to buy this flagging pot stock?